Potent high-avidity neutralizing antibodies and T-cell responses after COVID-19 vaccination in patients with B-cell lymphoma and multiple myeloma. Keppler-Hafkemeyer et al.
Published: 18 November 2022| Version 1 | DOI: 10.17632/z6dw96y8sw.1
Pseudonymized patient record data as well as raw data from antibody, avidity, and live-virus neutralization measurements in patients with hematopoietic neoplasia and healthy donors.
Severe Acute Respiratory Syndrome Coronavirus 2